Showing all 3 results
ALK Fusion – FISH is a fluorescence in situ hybridization (FISH) test designed to detect ALK gene rearrangements in tumor samples, primarily for non-small cell lung cancer (NSCLC) patients. Key features include high sensitivity and specificity, FDA approval for clinical diagnostics, and direct visualization of ALK gene fusions at the cellular level.
The HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment. This test offers higher sensitivity and specificity compared to immunohistochemistry (IHC), reducing false-positive or false-negative results. Its rapid turnaround time and clinically validated methodology make it a gold standard for personalized cancer treatment, ensuring optimal therapeutic decisions and improved patient outcomes.
The **Hereditary Cancer Gene Panel (57 ACMG Genes)** is a comprehensive genetic test designed to assess inherited cancer risk by analyzing 57 clinically significant genes recommended by the **American College of Medical Genetics (ACMG)**. This panel identifies mutations linked to various hereditary cancers, including **breast, ovarian, colorectal, prostate, and pancreatic cancers**, enabling early detection and personalized risk management. Key features include **next-generation sequencing (NGS) technology** for high accuracy, expert-reviewed results, and actionable insights for **preventive care and targeted treatment strategies**. Ideal for individuals with a family history of cancer, this test empowers proactive healthcare decisions, offering **lifelong benefits through early intervention and precision medicine**.